Tuberculosis (TB) is one of the most fatal diseases and is responsible for the infection of millions of people around the world. Most recently, scientific frontiers have been engaged to develop new drugs that can overcome drug-resistant TB. Following this direction, using a designed scaffold based on the combination of two separate pharmacophoric groups, a series of menadione-derived selenoesters was developed with good yields. All products were evaluated for their
in vitro
activity against
Mycobacterium tuberculosis
H37Rv and attractive results were observed, especially for the compounds
8a
,
8c
and
8f
(MICs 2.1, 8.0 and 8.1 μM, respectively). In addition,
8a
,
8c
and
8f
demonstrated potent
in vitro
activity against multidrug-resistant clinical isolates (CDCT-16 and CDCT-27) with promising MIC values ranging from 0.8 to 3.1 μM. Importantly, compounds
8a
and
8c
were found to be non-toxic against the Vero cell line. The SI value of
8a
(>23.8) was found to be comparable to that of isoniazid (>22.7), which suggests the possibility of carrying out advanced studies on this derivative. Therefore, these menadione-derived selenoesters obtained as hybrid compounds represent promising new anti-tubercular agents to overcome TB multidrug resistance.